<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html><!-- InstanceBegin template="../../../Templates/data.dwt" codeOutsideHTMLIsLocked="false" -->
<head>
<!-- InstanceBeginEditable name="doctitle" --> 
<TITLE>PNI.org | Pacific Neuropsychiatric Institute</TITLE>
<!-- InstanceEndEditable --> 
<META NAME="description" CONTENT="The Pacific Neuropsychiatric Institute
(PNI) is involved with comprehensive evaluation and management in
Neuropsychiatry and Psychopharmacology at the clinical, research,
forensic, education and phenomenologic levels.">
<META NAME="keywords" CONTENT="Vernon Neppe, medicine, psychopharmacology,
neuropsychiatry, forensic psychiatry, neuropsychiatric, institute,
education, lectures, brain, forensics, journal, internet journal, Neppe,
neurotransmitters, medical ethics, questionnaire, research instruments,
caffeine, philosophy, vortex pluralism, epileptology, anomalous, informed
consent, pharmacology, neuropsychology, clinical medicine, mental health,
brain injury, epilepsy, seizure, head injury, deja vu, anomalistic
experience, parapsychology, phenomenology, psychiatric, medical, drug,
BROCAS SCAN, STRAW, INSET, NMBPRS, PBRS, mental status, MMPI, SCL-90,
MMSE, Electroencephalogram, Electroencephalography, EEG, Ambulatory
monitoring, Ambulatory EEG, ventricular dilatation, MRI head, CT head,
SPECT head, PET head, competency, statistics, litigation, competence,
deposition, evidence, ethics, pharmacokinetics, pharmacodynamics, P450,
side-effects, tachyphylaxis, FDA, in vitro, in vivo, receptorology, civil
litigation, DSM, internet journal of Neuropsychiatry and
Psychopharmacology, JINEPP, INEPP, medical books, innovative
psychopharmacotherapy, partial agonist, agonist, antagonist, receptor,
synapse, autoreceptor, post-synaptic, pre-synaptic, down regulation, up
regulation, supersensitivity, subsensitivity, GABA, NMDA, receptor
subtypes, serotonin, norepinephrine, acetylcholine, benzodiazepine,
dopamine, opiates, chloride ionophore, pituitary, hypothalamus, temporal
lobe, frontal lobe, parietal lobe, occipital lobe, cerebral cortex,
kindling, chindling, bathtub, pushbuttons, motivation, MSE, mental status
examination, cognition, affect, volition, lesion localization,
psychomotor, dangerousness, environmental interaction, memory,
concentration, normality, organic brain syndrome, behavioral neurologist,
sleep, obesity, bariatric medicine, EMG, Electromyography, Nerve
conduction, antidepressant, anxiolytic, anxioselectivity, psychostimulant,
beta blocker, beta blockade, anticonvulsant, adjunctive therapy, appetite
suppressants, computer therapy, computerized diagnosis, memory retraining,
speech retraining, neuropharmacology, neuropharmacologist,
psychopharmacology, psychopharmacologist, anxiety, depression, OCD, ADD,
ADHD, attention deficit hyperactivity disorder, aggression, irritability,
tardive dyskinesia, movement disorder, neurology, Parkinson's, headache,
pain, sexual dysfunction, fibromyalgia, obsessive compulsive, Alzheimer's,
seizure, epilepsy, epileptic, TLE, CPS, closed head injury, CHIT, CHIP,
MTBI, PTSD, traumatic brain injury, methylphenidate, Ritalin, zolpidem,
Ambien, nadolol, Corgard, pemoline, Cylert, selegeline, nitrous oxide,
azapirones, phenytoin, Dilantin, topiramate, Topamax, tiagabine, Gabitril,
valproate, Depakote, felbamate, Felbatol, gabapentin, Neurontin,
carbamazepine, Tegretol, lamotrigine, Lamictal, neuroleptics, sumatriptan,
Imitrex, Sinemet, carbidopa, SSRI, sertraline, paroxetine, fluvoxamine,
fluoxetine, Zoloft, Paxil, Prozac, Luvox, bupropion, Wellbutrin, tricyclic
antidepressant, amitriptyline, imipramine, bromocriptine, Eldepryl,
Aricept, donepezil, pergolide, Cognex, tacrine, Parlodel, cyclobenzaprine,
Flexeril, phentermine, Buspar, buspirone, nefazodone, Serzone,
venlafaxine, Effexor, clozapine, Clozaril, perphenazine, Trilafon,
mirtazapine, Remeron, recreational drugs, firearms, cigarette, marijuana,
cannabinol, herbal remedies, St John's Wort, anti-oxidant,
proanthocyanadin, vitamin, mineral, melatonin, herbal, cannabis, tea,
coffee, cola drinks, pyridoxine, vitamin, mineral, ascorbic acid,
ascorbate, B6, anxiety, neurosis, depression, post-traumatic stress
disorder, Alzheimer's, dementia, cognitive deterioration, premenstrual
syndrome, PMS, panic, eating disorders, migraine, schizophrenia, bipolar
illness, manic, depression, mania, temporal lobe dysfunction, phobia,
pervasive developmental disorder, PDD, autism, obsessive compulsive
disordor, psychosis, refractory conditions, narcolepsy, drug abuse,
alcoholism, extrasensory perception, ESP, delta, psi, afferent, efferent,
subjective, vortex, paranormal, psychic, psychokinesis, PK, out of body
experience, OOBE, OBE, near death experience, NDE, survival, veridical,
dream, telepathy, clairvoyance, precognition, retrocognition, mediumship,
ectoplasm, aura, psychometry, remote viewing, Ganzfeld, deja entendu,
geomagnetic, deja pense, deja senti, deja pressenti, anomalous,
spontaneous, reincarnation, forced choice, Zener cards, experient,
non-experient, altered state, consciousness, phenomenologic">

<LINK REL="stylesheet" TYPE="text/css" HREF="../../../styles.css">

<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">

<script language="JavaScript" type="text/JavaScript">
<!--
function MM_displayStatusMsg(msgStr) { //v1.0
  status=msgStr;
  document.MM_returnValue = true;
}
//-->
</script>
<!-- InstanceBeginEditable name="head" --><!-- InstanceEndEditable -->
</head>

<body text="#000000" link="#990000" vlink="#990000" alink="#990000" onLoad="MM_displayStatusMsg('PNI.org | Pacific Neuropsychiatric Institute');return document.MM_returnValue">
<a name="top"></a> 
<table width="700" border="1" align="center" cellpadding="0" cellspacing="0" bordercolor="#000000">
  <tr> 
    <td><table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="C4D2FF">
        <tr> 
          <td><a href="/"><img src="../../../header.jpg" width="700" height="127" border="0"></a></td>
        </tr>
        <tr>
          <td>
		  <div align="right">
				<a href="http://brainvoyage.com/" target="new_window">www.brainvoyage.com</a>
				 | <a href="http://vernonneppe.org/" target="new_window">www.vernonneppe.org</a>
				 | <a href="http://vernonneppe.com/" target="new_window">www.vernonneppe.com</a>
				 | <a href="http://ecao.us/" target="new_window">www.ecao.us</a>
				 | <a href="http://healthyharmony.com/" target="new_window">www.healthyharmony.com</a>&nbsp;
			</div>
			<div align="left" >
				<script>
				  (function() {
					var cx = '009175660163571863627:du9tocqgd6q';
					var gcse = document.createElement('script');
					gcse.type = 'text/javascript';
					gcse.async = true;
					gcse.src = 'https://cse.google.com/cse.js?cx=' + cx;
					var s = document.getElementsByTagName('script')[0];
					
					s.parentNode.insertBefore(gcse, s);
				  })();
				</script>
				<gcse:search></gcse:search>
			</div>
			<table width="100%" border="0" cellspacing="0" cellpadding="15">
              <tr>
                <td width="100%"><p><font size="3" face="Arial, Helvetica, sans-serif"><strong>
                    <a href="http://pni.org/neuropsychiatry/">NEUROPSYCHIATRY and BEHAVIORAL NEUROLOGY</a>
                     | 
                    <a href="http://pni.org/psychopharmacology/">PSYCHOPHARMACOLOGY</a><br><a href="http://pni.org/forensics/">FORENSICS</a> | <a href="/research/">RESEARCH</a>
					 | 
                    <a href="http://pni.org/consciousness/">CONSCIOUSNESS</a>
					 | 
                    <a href="http://pni.org/philosophy/">PHILOSOPHY</a> | <a href="http://www.brainvoyage.com/ctbm/">BOOKS</a> | <a href="/books/">LITERATURE</a><br>
                    <a href="http://pni.org/perspective.html">PERSPECTIVES</a>
                    | <a href="http://pni.org/clinical/">CLINICAL</a> | <a href="http://pni.org/research/anomalous/deja/">D&Eacute;J&Agrave; VU</a> | 
                    <a href="http://pni.org/interesting/">INTERESTING AREAS</a> | <a href="http://pni.org/philosophy/ethics/">ETHICS</a>
                    | <a href="http://pni.org/about_pni.html">CONTACT</a></strong></font></p>
                <p>
					<strong>
						KEY ARTICLES (MEDICAL):
						<a href="http://pni.org/neuropsychiatry/chit/">HEAD INJURY</a> | 
						<a href="http://pni.org/neuropsychiatry/narcolepsy/">NARCOLEPSY</a> | 
						<a href="http://www.pni.org/neuropsychiatry/paroxysmal/">PAROXYSMAL DISORDERS</a> | 
						<a href="http://pni.org/psychopharmacology/principles/">PRESCRIPTION PRINCIPLES</a> | 
						<a href="http://www.pni.org/psychopharmacology/generics">GENERIC SUBSTITUTION</a> | 
						<a href="http://www.pni.org/neuropsychiatry/tardive_dyskinesia/">TARDIVE DYSKINESIA</a> |
						<a href="http://pni.org/key-articles/double-blind.html">DOUBLE BLIND</a>
						</strong>
						<p>
					<strong>
						ENDURING INTEREST:
						<a href="http://www.pni.org/groundbreaking/">GROUNDBREAKING PARADIGM SHIFTS</a> | 
						<a href="http://www.pni.org/philosophy/">PHILOSOPHY</a> | 
						<a href="http://www.pni.org/neuropsychiatry/moral_philosophy/">MORAL PHILOSOPHY</a> | 
						<a href="http://www.pni.org/neuropsychiatry/consciousness/">CONSCIOUSNESS</a> | 
						<a href="http://pni.org/key-articles/deja-vu.html">DEJA VU</a> | 
						
						<a href="http://www.pni.org/intelligence/">GENIUS</a> | 
						
						<a href="http://www.pni.org/ethics/security/">ZMAIL</a>					
					 </strong>
				</td>
              </tr>
            </table>
            <table width="100%" border="0" cellspacing="0" cellpadding="0">
              <tr> 
                <td class="bodyText" valign="top"><!-- InstanceBeginEditable name="content" --> 
                  <table width="650" border="0" align="center" cellpadding="5" cellspacing="0">
                    <tr> 
                      <td width="74%" valign="top"> <H1>Clinical Implications 
                          of Serotonin 1A Neuromodulation</H1>
                        <P>Vernon M Neppe MD, PhD</P>
                        <H2>Educational Objectives</H2>
                        <OL>
                          <LI> To educate in the area of serotonin and particularly 
                            the serotonin 1A receptor subtype in the context of 
                            clinical psychiatry. </LI>
                          <LI> To discuss the clinical implications of the serotonin 
                            1A receptor with regard to management options and 
                            problems. </LI>
                          <LI> The development of a broader theory of innovative 
                            psychopharmacotherapy and the understanding of concepts 
                            such as neuromodulation and partial agonism. </LI>
                        </OL>
                        <H2>Abstract</H2>
                        <P> The serotonin receptors modulate a variety of basic 
                          functions at a large number of levels. These functions 
                          reflect serotonin 1A neuromodulators as well. The clinical 
                          application is broad because drug action at the serotonin 
                          1A receptor subtype involves low toxicity, lack of dependency 
                          and no sedation. Moreover, some serotonin 1A related 
                          compounds act selectively at that receptor. This combined 
                          with the uniqueness of the 1A subtype in acting at the 
                          autoreceptor in the raphe nucleus and post-synaptically 
                          in areas of the brain of strategic relevance to psychopathology 
                          makes their potential application in psychiatry and 
                          medicine substantial. Finally, the availability of post-synaptic 
                          partial agonists at the receptor level makes the application 
                          potentially enormous. </P>
                        <P> Serotonin 1A receptor action can be measured relatively 
                          specifically by the azapirones. These act as partial 
                          agonists postsynaptically and full agonists at the autoreceptor. 
                          Non-specifically, beta 2 -adrenergic receptor blockers 
                          (like propranolol) produce overall serotonin 1A receptor 
                          antagonist effects. The benzodioxines, an experimental 
                          group, which includes eltoprazine, act as partial agonists 
                          postsynaptically on both 5HT 1A and 1B receptors. Lithium 
                          has very non-specific effects but technically is a serotonin 
                          1A agonist. It is marketed for manic-depressive illness 
                          prophylaxis and treatment of mania (e.g. 450-1500 mg 
                          per day with serum levels such as 0.4 to 0.7 to 1.0 
                          meq / L). Similar doses have been used in open cases 
                          for aggression (not approved). </P>
                        <P> The literature on beta-blockers and the role of serotonin 
                          1A in this regard is reviewed. The perspectives in somatic 
                          anxiety, akathisia and aggression particularly may be 
                          relevant. Low doses of beta-blocker (e.g. 10 mg tid 
                          of nadolol or propranolol) may act peripherally on the 
                          beta-adrenergic receptor. Anti-akathisic effects require 
                          lipid solubility and beta-2 drugs implying 5HT 1A effects 
                          (e.g. 20mg tid of propranolol). Higher doses of lipid 
                          soluble beta-2-blocker such as propranolol in enormous 
                          doses (e.g. 240mg q.i.d. of propranolol monitored carefully 
                          because of safety considerations) have been occasionally 
                          used in aggression and probably are serotonin related. 
                        </P>
                        <P> Specific serotonin modulators are evaluated using 
                          the azapirones as the pharmacologic probe. Buspirone 
                          as the only marketed azapirone is approved for use only 
                          in anxiety and mixed anxiety depressive states, however, 
                          clinical experience in several other areas is interesting 
                          but still at various early research stages. </P>
                        <P> Low doses of buspirone (5-20mg ) probably act at the 
                          autoreceptor as agonists effectively producing post-synaptic 
                          antagonism across all serotonin receptor subtypes. These 
                          doses are provisionally excellent anti-aggressive agents 
                          using animal and human models. They may have adjunctive 
                          use in attention deficit disorder. Speculatively, they 
                          help SSRI induced akathisia: This effect may be post-synaptic 
                          partial agonism with the antagonist effect being uppermost 
                          (dosing 15-30mg per day). Medium doses act post-synaptically 
                          modulating the prophylaxis of anxiety (30-45mg /day). 
                          Higher doses are weak agonists and may correspond with 
                          weak antidepressant effects (45-60 mg / day). Serotonin 
                          1A partial agonism may imply adjunctive use of buspirone 
                          or other azapirones in instances when SSRI compounds 
                          stop facilitating depression. Higher doses may also 
                          imply some modulation of obsessionality (60mg / day), 
                          disputably post-traumatic stress disorder (60-75 mg 
                          / day) and even possible effects on the irritability 
                          of the manic (60-90 mg / day). Such doses also may induce 
                          mild akathisia: this may imply a serotonin 1A modulating 
                          role, but this is complex as serotonin re-uptake blockers 
                          like fluoxetine which act broadly also induce akathisia; 
                          moreover this can be blocked by buspirone. Finally extremely 
                          high doses of buspirone appear very promising anti-tardive 
                          dyskinesia agents (120-240 mg per day): as these effects 
                          may be tentatively blocked by cyproheptadine, this too 
                          may be via serotonin 1A neuromodulation of the known 
                          partial dopamine agonist effects of buspirone in conventionally 
                          supratherapeutic doses. The scanty literature is discussed. 
                        </P>

<P align="right"><font face="Arial, Helvetica, sans-serif"><a href="#top"><img src="../../../top.gif" width="48" height="19" border="0"></a></font></P></td>
                    </tr>
                  </table>
                  <p>&nbsp;</p>
                  <!-- InstanceEndEditable -->
<p>&nbsp;</p>
				  </td>
              </tr>
            </table>
            
          </td>
        </tr>
        <tr>
          <td height="29"><img src="../../../bottom.jpg" width="700" height="29" border="0" usemap="#Map3"></td>
        </tr>
      </table></td>
  </tr>
</table>
<p align="center"><br>
  <font size="2" face="Arial, Helvetica, sans-serif">Copyright &copy;1997-2018 
  Pacific Neuropsychiatric Institute</font><br>
</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<map name="Map3">
  <area shape="rect" coords="237,3,385,23" href="http://pni.org/about_pni.html">
  <area shape="rect" coords="410,5,566,25" href="http://www.pni.org/disclaimer.html">
  <area shape="rect" coords="582,3,682,26" href="http://www.pni.org/credits.html">
</map>
</body>
<!-- InstanceEnd --></html>
